AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04919525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrainPain
Description: Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
Study NCT05136365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiongdan Wan
Description: Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
Study NCT05777720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtration Fan
Description: Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
Study NCT05777720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe-home pamphlet
Description: The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
Study NCT05777720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-week phone call
Description: On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
Study NCT05360082 — intervention group
Intervention type: OTHER
Intervention: [11C]UCB-J
Description: 11C-labeled SV2A binding PET radioligand
Study NCT05360082 — intervention group
Intervention type: OTHER
Intervention: [18F]SynVest-1
Description: 18F-labeled SV2A binding PET radioligand
Study NCT04640961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
Study NCT05716087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocbrutinib
Description: Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
Study NCT04722341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE)
Description: 8-hour daily eating period, starting 1-3 hours after waking up
Study NCT04722341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: More than equal to a 12-hour daily eating period
Study NCT05228730 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran - Standard dose
Description: Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.
Study NCT05228730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran - fractional dose
Description: Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
Study NCT05228730 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Elasomeran - standard dose
Description: Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
Study NCT05228730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elasomeran - fractional dose
Description: Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study.
Study NCT06120166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
Study NCT05679466 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: randomized, double-blinded, placebo-controlled
Description: Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
Study NCT05679466 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: randomized, double-blinded, placebo-controlled
Description: Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
Study NCT06638671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
Study NCT06638671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
Study NCT06267157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: Group that will receive breastfeeding training with virtual glasses, in the metaverse universe.
Study NCT06267157 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: theoretical breastfeeding training
Description: Classic 2-hour theoretical breastfeeding training with ppt
Study NCT04808986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serological test for the detection of IgG anti-SARS-CoV-2
Description: Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
Study NCT05821530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFIT
Description: At least 1 hour daily for 4 weeks
Study NCT05821530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: At least 1 hour daily for 4 weeks
Study NCT05821530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Users will continue to use the digital MSK program as needed
Study NCT05682079 — intervention group
Intervention type: OTHER
Intervention: TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity
Description: The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device.
Study NCT05903872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy massage
Description: aromatherapy massage was applied using essential oils
Study NCT05903872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: back massage
Description: back massage was applied using only almond oil
Study NCT05545033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 5 to 15 minutes of virtual reality exposure
Study NCT04822168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx™
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
Study NCT04822168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
Study NCT04640298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
Study NCT05501678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25mg (and up to 50mg) Diphenhydramine given orally
Study NCT05501678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo given orally
Study NCT04795843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and patient education
Description: Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.
Study NCT04795843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.
Study NCT06528964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry and immunofluorescence
Description: Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.
Study NCT06070194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating (TRE)
Description: Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks. Participants will be asked to continue habitual sleep patterns.
Study NCT05012982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirBand
Description: The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.
Study NCT05012982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uninflated AirBand
Description: Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed
Study NCT05781217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin, goserelin, leuprorelin
Description: ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
Study NCT03552796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03552796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given intravesically
Study NCT05671913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Treatment arm
Study NCT05671913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study NCT04637698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: Oncolytic Type 2 Herpes Simplex Virus
Study NCT06005389 — intervention group
Intervention type: PROCEDURE
Intervention: cryotherapy
Description: Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. Each wart was frozen using the spray technique by CRY-AC Liquid Nitrogen Dispenser Brymill, USA for 10 to 30 seconds until a 1- to 2-mm ice ball halo was formed surrounding the targeted area.
Study NCT06005389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum Galectin-3 assay
Description: From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.
Study NCT04825769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT（Low Level Laser Therapy）
Description: 2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
Study NCT05265910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine hydrochloride ophthalmic solution 0.7%
Description: Pataday® Once Daily Relief Extra Strength (eyedrop)
Study NCT05265910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loratadine 10 mg
Description: Claritin® Tablets 24-Hour (tablet)
Study NCT05265910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tears Naturale
Description: Tears Naturale® II (eyedrop)
Study NCT05265910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (tablet)
Study NCT06470412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
Study NCT06470412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Guided Group
Description: Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study NCT06503094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19&CD20 bispecific CAR-T cells
Description: Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
Study NCT04880447 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.
Study NCT05573321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR-RE
Description: In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
Study NCT05573321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR-RE
Description: In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
Study NCT05573321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HL-RE
Description: In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
Study NCT05573321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HL-RE
Description: In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
Study NCT05029466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.